{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
methylprednisolone succinate
to a specific field?
Status:
Investigational
Source:
INN:escibenzoline [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02593539: Phase 2 Interventional Completed Activated PI3K-delta Syndrome
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
GSK-2269557 (nemiralisib), a PI3Kδ inhibitor, is in development as an anti-inflammatory drug for the treatment of inflammatory airways disease. Studies in moderate or severe stable COPD patients have shown an acceptable safety and tolerability profile when GSK-2269557 was administered via inhalation. Cough was the most commonly reported adverse event.
Status:
Investigational
Source:
NCT04676516: Phase 2 Interventional Completed Breast Cancer
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04116541: Phase 2 Interventional Recruiting Malignant Solid Tumor
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00195325: Phase 1 Interventional Terminated Tumors
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Cevipabulin is a synthetic, water-soluble tubulin-binding agent with potential antineoplastic activity. Cevipabulin appears to bind at the vinca-binding site on tubulin but seems to act more similar to taxane-site binding agents in that it enhances tubulin polymerization and does not induce tubulin depolymerization. The disruption in microtubule dynamics may eventually inhibit cell division and reduce cellular growth.
Class (Stereo):
CHEMICAL (UNKNOWN)
Tazadolene was developed as a novel non-opioid analgesic with antidepressant properties. Experiments on rodents have revealed that unique analgesia properties of tazadolene was due to the ability of this compound to activate both serotonergic and alpha 2 adrenergic antinociceptive systems. Information about the current use of this drug is not available.
Class (Stereo):
CHEMICAL (UNKNOWN)
Tazadolene was developed as a novel non-opioid analgesic with antidepressant properties. Experiments on rodents have revealed that unique analgesia properties of tazadolene was due to the ability of this compound to activate both serotonergic and alpha 2 adrenergic antinociceptive systems. Information about the current use of this drug is not available.
Status:
Investigational
Source:
NCT00336713: Phase 3 Interventional Completed Depressive Disorder
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Sanofi aventis developed saredutant (also known as SR 48968C) as a tachykinin neurokinin-2 (NK2) receptor antagonist for the treatment of depressive disorders and generalized anxiety disorder. This drug participated in phase III clinical trials in patients with a generalized anxiety disorder and as Combination Treatment for major depressive disorder, however, the drug failed to meet efficacy endpoints. It is known that NK-2 receptor mediates airway obstruction that is why saredutant was studied as a potential treatment of asthma. However, all studies of the drug were discontinued.
Status:
Investigational
Source:
NCT02573870: Phase 2 Interventional Completed Pulmonary Disease, Chronic Obstructive
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Batefenterol, previously known as GSK961081, a bifunctional muscarinic (M2 and M3 receptors) antagonist β2-agonist that is developed for chronic obstructive pulmonary disease (COPD). The drug has successfully completed phase II clinical trials with clinically significant improvements in lung function. No new or unexpected safety signals were observed in this COPD population. The conclusion from the trial was following that batefenterol 300 µg might represent the optimal dose for Phase III studies.
Status:
Investigational
Source:
USAN:ULODESINE SUCCINATE [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
